BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 19383313)

  • 1. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
    Platz A; Egyhazi S; Ringborg U; Hansson J
    Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
    J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
    Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
    Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
    Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving melanoma classification by integrating genetic and morphologic features.
    Viros A; Fridlyand J; Bauer J; Lasithiotakis K; Garbe C; Pinkel D; Bastian BC
    PLoS Med; 2008 Jun; 5(6):e120. PubMed ID: 18532874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
    Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
    J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of NRAS and BRAF mutations in cutaneous melanoma.
    Rosso R; Romagosa Y; Kirsner RS
    J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.
    Kannengiesser C; Spatz A; Michiels S; Eychène A; Dessen P; Lazar V; Winnepenninckx V; Lesueur F; Druillennec S; Robert C; van den Oord JJ; Sarasin A; Bressac-de Paillerets B;
    Mol Oncol; 2008 Apr; 1(4):425-30. PubMed ID: 19383316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
    Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
    J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations.
    Colombino M; Paliogiannis P; Pagliarello C; Cossu A; Lissia A; Satta R; Mazzoni L; Magi S; Sini MC; Manca A; Casula M; Doneddu V; Palmieri G; Stanganelli I
    Eur J Dermatol; 2018 Apr; 28(2):149-156. PubMed ID: 29180316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.